Introduction {#s1}
============

The onset of psychotic illness typically occurs in late adolescence or early adulthood. This first episode of psychosis (FEP) is suffered by about 3% of the population ([@CIT0036]) and its clinical evolution tends to chronicity. Up to 80% of the patients relapse during the next 5 years after a FEP, with major risk to become resistant to treatment. Complete remission occurs in only one-third of the patients ([@CIT0019]).

The FEP population represents a unique opportunity to evaluate biological, clinical, and functional outcomes of psychotic disorders: research at the onset of illness avoids the effect of confounding variables (Khan et al., 2008; [@CIT0003]) and early intervention mitigates progression and improves prognosis ([@CIT0026]).

Despite all the great efforts made involving basic and clinical science, we are still far from a complete understanding of the pathophysiology of the disorder. Not surprisingly, \<50% of patients respond to initial treatments ([@CIT0025]). In the past 15 years, a great deal of interest has been focused on immune/inflammatory alterations and the oxidative/nitrosative consequences as key pathophysiological mechanisms involved ([@CIT0034]; [@CIT0007]). Although most of the scientific evidence has been found in established schizophrenia, some studies indicate subtle alterations in inflammatory/immune mediators and oxidative/nitrosative stress at the very beginning of the disease ([@CIT0005]; [@CIT0029]). Moreover, neuroimaging studies demonstrate that neuroinflammation is already present in early stages of schizophrenia ([@CIT0035]).

In contrast, fewer studies have focused on the role of antiinflammatory signaling pathways, the counterbalancing mechanisms that control the potentially deleterious proinflammatory mediators ([@CIT0010]). Recent data show a clear systemic misbalance in some pro-/antiinflammatory mediators in patients with schizophrenia ([@CIT0030]). Also, the increase of antiinflammatory cytokines (transforming growth factor beta and interleukin 10) seems to be a mechanism elicited by several antipsychotics ([@CIT0032]).

Recently, Flamm-PEPs, a multicenter study inside the Spanish national network for mental health research, presented the first integrated results about the imbalance of pro-/antiinflammatory components in peripheral blood mononuclear cells (PBMCs) in FEP patients ([@CIT0011]). In particular, the proinflammatory pathway studied was the canonical one triggered by the activation of the nuclear transcription factor κB (NFκB) (Bierhaus et al., 2001; [@CIT0028]). NFκB activates specific DNA sequences in the promoter of target genes, such as those that codify for the inflammatory enzymes inducible nitric oxide synthase (iNOS) and the isoform 2 of cyclooxygenase (COX2). The overactivation of the enzymes produces an increase in oxidative and nitrosative mediators (ie, stable NO metabolites such as NO^−^ ~x~, prostaglandins such as PGE~2~), which can cause the depletion of endogenous antioxidant defences and attack membrane phospholipids, causing cell damage by lipid peroxidation ([@CIT0010]). On the other hand, endogenous counterbalancing mechanisms are activated in response to inflammatory/immune stimuli, such as peroxisome proliferator activated receptors (PPARs). These nuclear receptors (mainly their gamma isoform, PPARγ; [@CIT0015]) act as ligand-dependent transcription factors, decreasing the expression of proinflammatory genes. Interestingly, several COX-derived products, such as the prostaglandin 15-deoxy-PGJ~2~ (15d-PGJ~2~), act as endogenous antiinflammatory agents by targeting PPARγ ([@CIT0009]). Thus, the 15d-PGJ~2~/PPARγ pathway is an endogenous compensatory mechanism. This pathway could also be pharmacologically stimulated, representing not only a potential biomarker but also an important new candidate therapeutic target in those neuropsychiatric disorders in which inflammation may be playing a role.

In short, the above-cited first study of Flamm-PEPs ([@CIT0011]) also showed a decrease in the 15d-PGJ~2~/PPARγ pathway, demonstrating a proinflammatory phenotype in patients during their first 6 months after diagnosis. The disruption of this physiological balance is again reexamined in the present follow-up study 12 months after the inclusion of the patients in order to (1) analyze the evolution of the balance described in FEP, (2) identify potential risk/protective factors, (3) recognize associations between pro-/antiinflammatory mediators and symptoms' severity during follow-up, and finally (4) by means of multiple linear regression models, to analyze the change of every biological marker during follow-up in relation to clinical characteristics and confounding factors.

Methods and Materials {#s2}
=====================

Subjects (see supplementary Material 1 for complete details) {#s3}
------------------------------------------------------------

A total of 117 FEP subjects and 106 gender-, race-, and age-matched healthy controls were included in the baseline Flamm-PEPs study ([@CIT0011]). From the initial sample, 85 FEP subjects were followed during the next 6 months (maximum 12 months after inclusion). Baseline inclusion criteria for patients were: (1) age: 7 to 45 years; (2) duration of the psychotic symptoms: \<1 year; and (3) speak Spanish correctly. The exclusion criteria were: (1) mental retardation (IQ \<70 together with impaired functioning); (2) history of traumatic head injury with loss of consciousness; and (3) history of organic disease with mental repercussions. Having designed a real-life patient, naturalistic study, substance use, or having suicidal ideation were not exclusion criteria ([@CIT0003]). Controls were selected from the same geographic areas. Inclusion criteria were: (1) same gender as patients; (2) similar age (±10%); (3) similar paternal socioeconomic status, allowing ±1 level in the Hollingshead-Redlich scale ([@CIT0016]); (4) no past or present psychiatric disorder per DSM-IV criteria; (5) speak Spanish correctly; and (6) no history of psychotic disorder among first-degree relatives. The exclusion criteria for controls were the same as for patients.

Neither the patients nor the controls presented ongoing infections, fever, allergies, or other serious medical conditions or were receiving immunosuppressive drugs or vaccinations for at least 6 months prior to inclusion in the study or antiinflammatory-analgesics in the 2 days previous to blood extraction. Clinical assessment of patients and controls included a complete medical history, physical examination, electrocardiogram, and laboratory tests ([@CIT0003]).

Expert clinicians used the Spanish translation of the DSM-IV semistructured diagnostic interview to establish diagnosis in adults ([@CIT0006]) and the Kiddie-Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version for subjects younger than 18 years old ([@CIT0041]). There was a broad age of inclusion to allow the inclusion of early-onset psychotic patients ([@CIT0003]). Medical records and interviews with relatives were used as other sources of information to establish the onset of positive symptoms. The onset of the FEP was defined as the first week with the Positive and Negative Syndrome Scale (PANSS) items P1, P3, P5, P6, or G9 scoring ≥4 ([@CIT0011]). Global Assessment of Functioning scale (GAF) is a numerical scale (0--100) that measures functionality of patients based on work and social adjustment ([@CIT0013]). The duration of untreated psychosis (DUP) was defined as the number of days elapsed between this onset and the beginning of the first antipsychotic treatment. DUBM was defined as the number of days elapsed between the onset of the FEP and blood sampling.

After complete description of the study to the subjects, written informed consent was obtained. The study was approved by the Ethics and Clinical Research Boards of all the hospitals involved in the study.

Specimen Collection and Preparation (see supplementary Material 1 for complete details) {#s4}
---------------------------------------------------------------------------------------

Venous blood samples (10mL) were collected between 8:00 and 10:00 [am]{.smallcaps} after overnight fasting. Blood tubes were centrifuged (641 *g* x 10 minutes, 4ºC). The resultant plasma samples were stored at −80ºC. The rest of the sample was diluted in culture medium (RPMI 1640, Invitrogen), and a gradient with Ficoll-Paque (GE Healthcare) was used to isolate mononuclear cells by centrifugation (800 *g* x 40 minutes, room temperature). The PBMC layer was aspired and resuspended in RPMI and centrifuged (1116 *g* x 10 minutes, room temperature). The supernatant was removed and the mononuclear cell enriched pellet was stored at −80 ºC.

Biochemical Determinations in Plasma (see supplementary Material 1 for complete details) {#s5}
----------------------------------------------------------------------------------------

Prostaglandins, the COX by-products PGE~2~ and 15d-PGJ~2~, were determined by enzyme immunoassay (Cayman Chemicals and DRG Diagnostics, respectively). Nitrites (NO^−^ ~2~), the final and stable product of NO, were determined by using the Griess method. Lipid peroxidation was determined by Thiobarbituric Acid Reactive Substances (TBARS) assay (Cayman Chemicals, Tallin, Estonia), and cotinine levels, the major degradation product of nicotine metabolism, were determined by enzyme immunoassay (Cozart).

Biochemical Determinations in PBMC (see supplementary Material 1 for complete details) {#s6}
--------------------------------------------------------------------------------------

PBMC samples were first fractionated in cytosolic and nuclear extracts. Determination of proinflammatory p65 NFκB subunit and ant-inflammatory PPARγ respective transcriptional activities were carried out in nuclear extracts from PMBC.

### NFκB Activity {#s7}

Activation of NFκB occurs by enzymatic degradation of the bound inhibitory protein (IκBα), allowing movement from cytoplasm to the nucleus where they bind to consensus κB sequences in DNA. The presence of p65 subunit in cell nuclei is considered an index of activity measured with a transcription factor assay (Cayman Chemicals, Tallin, Estonia).

### PPARγ Transcription Factor {#s8}

PPARγ transcription factor activity was determined using ELISA-based kits (Cayman Chemicals, Tallin, Estonia).

### Western-Blot (WB) Analysis {#s9}

Protein levels of IκBα, COX2, and iNOS were quantified by WB in cytosolic extracts from PBMCs. Protein levels of PPARγ were quantified in nuclear extracts. The housekeeping gene β-actin was used as loading control. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as loading control for PPARγ (blots shown in the respective figures). For clarity, 2 WBs are presented in the figures representative of all the samples studied (in each different gel, n=3 per group control or FEP).

Statistical Analysis (see supplementary Material 1 for complete details) {#s10}
------------------------------------------------------------------------

Differences between baseline characteristics for patients and controls were assessed using chi-square, *t* test, or nonparametric Mann-Whitney U tests according to the distribution and scales of the variables. The effect of psychotropic medication was evaluated with linear regression models for each biomarker. To calculate the association between FEP and the level of biological markers, 5 hierarchical logistic regression models were used in which we gradually controlled for potential confounders (age, gender, body mass index \[BMI\], cannabis use per month, and cotinine levels). Multiple linear regression analysis was used to analyze the change in each biological marker depending on the change in demographic (gender, age, BMI), clinical variables (DUP, DUBM, GAF), antipsychotic medication (defined daily dose \[DDD\]), and cannabis and tobacco (cotinine).

Results {#s11}
=======

Demographic and Clinical Features {#s12}
---------------------------------

[Table 1](#T1){ref-type="table"} presents the demographic and clinical characteristics of the FEP patients and the healthy control group. There were 32 subject from the total 117 FEP subjects who did not follow the 6-month period of study. Because of these early drop-outs, there were differences in the socioeconomic status between the groups that were not present at baseline.

###### 

Demographic and Clinical Characteristics

  Characteristic                                         Patients Baseline (N=85)   Patients Follow-up (N=85)   Controls (N=106)
  ------------------------------------------------------ -------------------------- --------------------------- ------------------
  Demographic characteristics                                                                                   
  Age, y                                                 24.89±6.26                 25.21±6.03                  25.18±6.79
  Sex, n (%)                                                                                                    
   Male                                                  60 (70.6)                  **---**                     70 (66.0)
   Female                                                25 (29.4)                  ---                         36 (34.0)
  Psychiatric history                                                                                           
  Socioeconomic status                                                                                          
   High                                                  16 (18.8)                  ---                         14 (13.2)
   Medium-high                                           7 (8.2)                    ---                         17 (16.0)
   Medium                                                30 (35.3)\*                ---                         54 (50.9)
   Medium-low                                            24 (28.2)                  ---                         19 (17.9)
   Low                                                   8 (9.4)\*                  ---                         2 (1.9)
  Ethnic group                                                                                                  
   Caucasian                                             79 (92.9)                  ---                         96 (90.6)
   Gipsy                                                 1 (1.2)                    ---                         0 (0)
   Maghrebian                                            1 (1.2)                    ---                         2 (1.9)
   Asian                                                 1 (1.2)                    ---                         0 (0)
   Caribbean                                             1 (1.2)                    ---                         0 (0)
   Hispanic                                              2 (2.4)                    ---                         6 (5.7)
   Other                                                 0 (0)                      ---                         2 (1.9)
  Age of psychosis onset                                 24.37±5.92                 ---                         ---
  DUP, d                                                 68.58±77.28                ---                         ---
  Diagnosis -- no. (%)                                                                                          
   Affective Psychosis                                   17 (20.0)                  17 (20.0)                   ---
   Non-affective Psychosis                               68 (80.0)                  68 (80.0)                   ---
  Psychopathology score                                                                                         
  PANSS                                                                                                         
   Total                                                 51.72±19.23                40.29±23.67                 ---
   Positive                                              10.67±5.38                 8.01±5.03                   ---
   Negative                                              14.58±6.26                 11.76±8.15                  ---
   General                                               26.47±9.75                 20.52±11.99                 ---
  Young                                                  1.45±3.25                  1.39±3.57                   ---
  Montgomery-Asberg                                      6.51±6.52                  6.02±6.94                   
  Overall functioning score (GAF)                        68.6±13.88                 72.08±17.23                 ---
  Antipsychotic medication, n (%)                                                                               
   Risperidone                                           30 (35.3)                  21 (25.9)                   ---
   Olanzapine                                            9 (10.6)                   6 (7.4)                     ---
   Aripiprazole                                          9 (10.6)                   15 (18.5)                   ---
   Paliperidone                                          7 (3.7)                    5 (6.2)                     ---
   Clozapine                                             5 (5.9)                    6 (7.4)                     ---
   Quetiapine                                            6 (7.1)                    5 (6.2)                     ---
   Ziprasidone                                           2 (2.4)                    2 (2.4)                     ---
   None                                                  17 (8.9)                   21 (25.9)                   ---
  Defined daily dose of chlorpromazine equivalents, mg   282.19±253.04              298.06±303.16               ---
  Lithium use, n (%)                                     8 (9.4)                    7 (8.4)                     ---
  Body mass index                                        24.83±3.81\*               24.65±5.73 \*               23.14±3.16
  Cannabis use, n (%)                                    18 (21.18)                 4 (5.1) \*                  14 (16.0)
  Cannabis use per month, n cigarettes                   4.71±19.36                 1.09±6.37                   1.15±6.36
  Tobacco use, n (%)                                     49 (57.6)                  54 (65.1)\*                 25 (29.4)
  Tobacco use per month, n cigarettes                    238.9±259.08               241.98±254.11\*             45.38 (119.31)
  Cotinine, ng/mL                                        86.73±84.46                97.27±84.50\*               26.28±49.31

Abbreviations: DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale.

\* ***P***\<.05. Comparison between patients: follow-up and healthy controls.

Inflammatory and Oxidative/Nitrosative Stress Markers in Control and FEP Patients {#s13}
---------------------------------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} shows mean differences (SD) in inflammatory and oxidative/nitrosative stress markers in control and FEP patients. NFκB is a master regulator of the inflammatory and oxidative/nitrosative status of a cell. In nuclear extracts from PMBCs, its activity is increased in FEP samples (supplementary Material 2 and [Figure 1a](#F1){ref-type="fig"}). Similarly, COX2 expression was significantly higher in FEP subjects, although the expression of iNOS was not different between groups (supplementary Material 2 and [Figure 1b](#F1){ref-type="fig"}-c). At this particular stage of the disease, the plasma levels of PGE~2~, NO^−^ ~2~, and TBARS were increased in FEP (supplementary Material 2 and [Figure 1d](#F1){ref-type="fig"}-f, respectively). The numerical data for WB analysis from all subjects have been included in supplementary Table S3.

![Mean differences (SD) in proinflammatory biomarkers between first episode of psychosis (FEP) and controls (univariate analysis). (a) Nuclear transcription factor κB (NFκB) activity in peripheral blood mononuclear cell (PBMC) nuclear extracts from FEP patients (*n* = 85) and controls (*n* = 35). (b) Western-blot analysis of isoform 2 of cyclooxygenase (COX2) protein (patients *n* = 85, controls, *n* = 88); (c) Inducible nitric oxide synthase (iNOS) in PBMC cytosolic extracts from FEP patients (*n* = 85) and controls (*n* = 88); and (d) PGE~2~ (patients, n = 85; controls, n = 104). (e) Plasma levels of nitrites (NO^−^ ~2~) (patients, n = 85; controls, n = 61). (f) Thiobarbituric acid reactive substances (TBARS) (patients, n = 85; controls, n = 104). AU, arbitrary units. Two-tailed nonparametric Mann-Whitney *U* test was used. ° represents an atypical value and \* an extreme value.](ijnppy_pyu037_f0001){#F1}

Antiinflammatory Markers in Control and FEP Patients {#s14}
----------------------------------------------------

[Figure 2](#F2){ref-type="fig"} shows mean differences (SD) in antiinflammatory and oxidative/nitrosative stress markers in control and FEP patients. IκBα in cytosolic extracts was not decreased in patients compared with healthy subjects (supplementary Material 2; [Figure 2a](#F2){ref-type="fig"}). However, plasma levels of the antiinflammatory 15d-PGJ~2~ were significantly lower in FEP (supplementary Material 2; [Figure 2b](#F2){ref-type="fig"}).

![Mean differences (SD) on antiinflammatory biomarkers. (a) Western-blot analysis of bound inhibitory protein (IκBα) in peripheral blood mononuclear cell (PBMC) cytosolic extracts (patients, n = 85; controls, n = 88); (b) Plasma levels of prostaglandin 15d-PGJ~2~ (patients, n = 85; controls, n = 104). (c) Western-blot analysis of peroxisome proliferator activated receptor γ (PPARγ; patients, n = 85; controls, n = 16). (d) Transcriptional activity of PPARγ (patients, n = 85; controls, n = 87) in PBMC nuclear extracts. AU, arbitrary units. Two-tailed *t* test was assessed for PPARγ protein levels, and for the rest of variables, 2-tailed nonparametric Mann-Whitney *U* test was used. ° represents an atypical value and \* an extreme value.](ijnppy_pyu037_f0002){#F2}

Given that 15d-PGJ~2~ acts as an endogenous ligand for PPARγ, which is considered a potent antiinflammatory transcription factor, we analyzed its expression and transcriptional activity. WB analysis revealed lower expression of PPARγ in patients (supplementary Material 2; [Figure 2c](#F2){ref-type="fig"}). Moreover, its transcriptional activity was also reduced in the patient group (supplementary Material 2; [Figure 2d](#F2){ref-type="fig"}).

Multiple Logistic Regression Analysis {#s15}
-------------------------------------

In the final multiple logistic regression model, 6 of 10 biological markers studied were significantly associated with followed FEP after controlling for all possible confounders ([Table 2](#T2){ref-type="table"}; supplementary Material 4). The resulting equation allows the estimation of the individual probability of FEP during a 6-month follow-up by substituting values of the biological levels and the demographic and clinical variables: *log* (P/1−P)=7.783+\[0.005xPGE2\]+\[0.017xCOX2\]+\[0.369xNO-2\]+\[0.182xTBARS\]+\[−0.832xPPARγ act\]+\[−0.023x15d-PGJ2\]+\[0.062xgender (male)\]+\[−0.194xage\]+\[−0.070xBMI\]+\[−0.014xcannabis use per month\]+\[0.034xcotinine\] ([@CIT0018]).

###### 

Multivariate Logistic Regression Analysis

                   B        SE      Wald     OR      CI 95%         *P*
  ---------------- -------- ------- -------- ------- -------------- ----------
  PGE~2~           0.005    0.002   3.721    1.005   1.000--1.009   .054
  **COX2**         0.017    0.007   6.509    1.017   1.004--1.031   **.011**
  **NO^-^~2~**     0.369    0.163   5.137    1.447   1.051--1.991   **.023**
  TBARS            0.182    0.162   1.269    1.200   0.874--1.649   .260
  PPARγ act        −0.832   0.631   1.741    0.435   0.126--1.498   .187
  **15d-PGJ~2~**   −0.023   0.007   10.099   0.977   0.963--0.991   **.001**

Abbreviations: B, median; COX-2: cyclooxygenase 2; CI, confidence interval; NO-2, nitrites; OR, odds ratio; PGE2, prostaglandin E2; PPARg act, peroxisome proliferator activated receptors activity; SE, standard error; TBARS, thiobarbituric acid reactive substances; 15d-PGJ2, prostaglandin 15-deoxy-PGJ2.

Association between FEP and level of biomarker. All the biomarkers were analyzed together and adjusted for age, gender, body mass index, cannabis use per month, and cotinine level. The bold values in the table represent the values reaching statistical significance (*P*\<.05).

Among the proinflammatory markers, the highest OR observed was for NO^−^ ~2~ (OR=1.447), meaning that for each unit increased of this biomarker, the risk of FEP increased by 44.7% \[(e^0.369x1^−1)x100\] after controlling for remaining biological markers and all possible confounders (*P*=.023). Similarly, the results were 20% for TBARS (not significant), 1.7% for COX2 (*P*=.011), and 0.5% for PGE~2~ (not significant).

Among the antiinflammatory markers, the PPARγ activity had the lowest OR observed (OR=0.435), meaning that the risk decreased by 56.5% \[(e^−0.832^x1−1)x100\] for each unit of increased biomarker after controlling for remaining biological markers and all possible confounders, although it was not significant (*P*=.187). Similarly, the result for 15d-PGJ2 was 2.3% (*P*=.001).

Multiple Linear Regression Analysis {#s16}
-----------------------------------

By means of multiple linear regression analysis, it is possible to predict the change of each biological marker from baseline to the follow-up point (6 to 12 months) controlling for a set of explanatory variables: gender, age, BMI, cannabis use, plasma cotinine levels, DDD of chlorpromazine equivalents, the DUP and the GAF scale score, and the days from diagnostic to the blood sampling for basal values (DUBM). Four (PGE~2~, COX2, NO^−^ ~2~, and TBARS) of the 6 proinflammatory and oxidative/nitrosative biological markers studied and 2 (15dPGJ~2~ and PPARγ activity) of the 4 antiinflammatory markers studied were significantly associated with some of the explanatory variables ([Table 3](#T3){ref-type="table"}).

###### 

Differences (Mean ± SD) in the Biomarker Levels between Baseline (6 Months After Diagnosis) and 1-Year Follow-Up Patients

  Marker                 Patients Baseline (N=85)   Patients Follow-Up (N=85)   Statistics   *P*
  ---------------------- -------------------------- --------------------------- ------------ ------------
  **iNOS -WBc-**         131.44±51.43               **109.05±52.89**            Z=−2.47      **.013**
  **COX2 -WBc-**         161.08±164.82              **230.60±169.86**           Z=−3.13      **.002**
  NFκB -act-             12.13±23.75                5.52±2.75                   Z=−0.20      .845
  **PGE~2~ -sol-**       522.29±770.33              **870.02±741.96**           Z= −4.58     **\<.001**
  NO^-^ ~2~ -sol-        14.94±6.20                 17.61±7.34                  Z=−1.88      .060
  **TBARS -sol-**        3.65±3.81                  **4.50±1.75**               Z=−3.69      **\<.001**
  IκBα -WBc-             86.36±49.97                104.21±82.09                Z=−0.73      .468
  **15d-PGJ~2~ -sol-**   571.25±154.15              **408.89±150.69**           Z=−5.72      **\<.001**
  **PPARγ -WBn-**        79.45±33.51                **55.94±49.09**             Z=−2.35      **.019**
  PPARγ -act-            1.29±0.93                  1.09±0.55                   Z=−1.11      .267

**Abbreviations:** act, activity assay in nuclear extracts; sol: plasma levels of soluble compounds; COX-2, cyclooxygenase 2; IkBa, inhibitor of the NFkB alpha; iNOS, inducible nitric oxide synthase; NFκB, nuclear transcription factor κB; NO-2, nitrites; PGE2, prostaglandin E2; PPARg, peroxisome proliferator activated receptor gamma; TBARS, thiobarbituric acid reactive substances; 15d-PGJ2, prostaglandin 15-deoxy-PGJ2.

Nonparametric Wilcoxon signed-rank test was used. The bold values in the table represent the values reaching statistical significance (*P*\<.05). Analyses carried out in WB: protein expression, determined by western blot in PBMC (WBc: in cytoplasmatic fraction; WBn: in nuclear fraction). See Methods for details.

Inflammatory and Oxidative/Nitrosative Stress Markers {#s17}
-----------------------------------------------------

The increased plasma levels of PGE~2~ from baseline to follow-up appeared negatively related to DDD (for each DDD unit increased during this period, PGE~2~ will decrease 0.733 units during follow-up, once controlling the effect of the increase in the other explanatory variables; [Table 4](#T4){ref-type="table"}). Also, PGE~2~ will decrease 3.387 units for each increase in 1 unit of cotinine plasma levels and will increase 0.714 units DUBM. COX2 expression was also related to cotinine: it will increase 0.672 units for each unit of cotinine level increased from basal to follow-up. The increase in nitrite levels also appeared related to the explanatory variables chosen: NO^−^ ~2~ increased by 7.451 units more in female patients than in male patients ([@CIT0024]).

###### 

Multiple Linear Regression Analysis

                           PGE~2~    COX2       NO^-^ ~2~   TBARS      15d-PGJ~2~   PPARγ act.                                                     
  ------------------------ --------- ---------- ----------- ---------- ------------ ------------ -------- ---------- --------- ---------- -------- ----------
  Gender (ref. female)     −45.635   .805       −37.395     .426       7.451        **.015**     1.793    .083       −31.095   .625       −0.179   .632
  Age                      −5.010    .759       −0.462      .915       −0.042       .870         0.108    .232       −11.284   .052       0.075    **.048**
  Body mass index          −1.898    .932       5.596       .281       −0.038       .903         −0.217   .073       2.463     .743       −0.141   .093
  Antipsychotic DDD        −0.733    **.028**   0.148       .085       0.006        .236         −0.001   .604       0.333     **.006**   0.000    .888
  DUP                      1.020     .462       0.187       .578       0.019        .355         −0.013   .080       −0.025    .957       0.003    .274
  GAF                      −3.401    .660       2.490       .206       0.122        .263         −0.120   **.005**   0.783     .763       −0.033   **.024**
  Cannabis use per month   −0.619    .890       −1.296      .215       −0.190       **.008**     0.015    .531       0.994     .510       −0.003   .714
  Cotinine plasma levels   −3.387    **.007**   0.672       **.046**   0.001        .955         0.001    .927       0.503     .225       0.002    .343
  DUBM                     0.714     **.017**   −0.047      .500       0.001        .837         0.005    **.002**   −0.057    .563       0.000    .555

Abbreviations: ß, linear regression coefficient; BMI, body mass index; DDD, defined daily dose of antipsychotic chlorpromazine equivalents; DUBM, number of days elapsed between the onset of the FEP and blood samplings; DUP, duration of untreated psychosis; GAF, Global Assessment of Functioning scale.

Change of each biological marker (from baseline to the follow-up point) depending on demographic and clinical variables. The bold values in the table represents the values reaching statistical significance (*P*\<.05).

The increase of TBARS plasma levels from basal to follow-up, the final marker of systemic oxidative/nitrosative stress, also appeared related to clinical status: for each unit of GAF scale increase, TBARS decreases 0.12 units. Finally, for DUBM, TBARS will increase 0.005 units.

Antiinflammatory Markers {#s18}
------------------------

Plasma levels of 15d-PGJ~2~ from baseline to the follow-up were positively related to DDD (for each DDD unit during this period, 15d-PGJ~2~ will increase 0.333 units during follow-up, once controlling the effect of the increase in the other explanatory variables; [Table 4](#T4){ref-type="table"}). Finally, the activity of PPARγ will decrease 0.033 units for each point in GAF score and increases 0.75 units for each year of age.

Discussion {#s19}
==========

In this follow-up study, we have strengthened the evidence of systemic inflammatory alterations in FEP patients. Previously, with this same cohort of patients, we described phenotypical differences in proinflammatory mediators at the cellular machinery level in PBMCs, but the resultant soluble elements were not significantly altered ([@CIT0011]). However, 6 months later, some of the soluble elements analyzed already appeared significantly altered (PGE~2~, TBARS, 15d-PGJ~2~), suggesting the existence of a deeper deregulation of the pro/antiinflammatory balance (supplementary Table S5).

The multivariate logistic regression analysis identified the plasma levels of the marker of oxidative/nitrosative damage NO^−^ ~2~ and the COX2 expression in PBMCs as the most reliable potential risk factors. Also, plasma levels of the antiinflammatory 15d-PGJ~2~ might be used as a potential protection factor for FEP.

The current longitudinal approach allowed the analysis of the changes of every biological marker between 6 and 12 months after the inclusion of the patients in relation to the changes of clinical characteristics and confounding factors. Especially remarkable are the associations found between the antipsychotic dose and the change in the plasma levels of PGE~2~ (inverse) and 15d-PGJ~2~ (direct). Indeed, these results suggest that one of the therapeutic mechanisms of antipsychotics may be the restoration of the pro-/antiinflammatory balance disrupted in FEP. It is worth noting that 25.9% of the FEP patients recruited here were receiving medication with risperidone, an atypical antipsychotic drug that normalizes increased inflammatory mediators (cytokines and inflammatory PGs) ([@CIT0040]; [@CIT0001]) and restores antiinflammatory pathways in murine models of neuroinflammation ([@CIT0027]). In our conditions, the increase of inflammation during follow-up can be due to the fact that antipsychotics are not able to completely reverse the inflammation associated with the disease, and this circumstance could justify the potential use of antiinflammatory drugs as coadjuvant to antipsychotics for the treatment of the psychotic disease ([@CIT0039]).

Other results deserving attention are the opposite relationships found between cotinine levels and COX-2 protein expression in PBMCs and PGE~2~ plasma levels. Nicotine effects on the cyclooxygenase pathway in an inflammatory context are complex and sometimes contradictory, depending of the nicotine levels reached, subtype of receptor activated, the route of administration of nicotine, and whether there is a subjacent pathological state ([@CIT0037]; [@CIT0012]; [@CIT0020]). Our paradoxical results need to be further explored to analyze the effects of nicotine on the antiinflammatory α7 nicotinic acetylcholine receptor ([@CIT0021]) or on the expression and enzymatic activity of tissue-specific PGE~2~ synthases, such as microsomal-PGE-synthase-1. Our results support the idea that cigarette smoking is a potent confounding factor to control for when the inflammation/innate immune system is studied.

Regarding other potential confounding factors, the results described here suggest that the alterations in the pro-/antiinflammatory balance in FEP patients are not related to changes in BMI in both time-points studied (see supplemental Table S6). In addition, NO^−^ ~2~ plasma levels increased more in female than in male patient subjects between both time points studied, age was directly related to PPARγ activity, and cannabis use per month was inversely related to NO^−^ ~2~ plasma levels. Further studies are needed to corroborate whether these relationships are particular for PEPs or can be extended to other states of psychotic disease. From a clinical point of view, the inverse relationship found between the GAF scale and TBARS plasma levels is particularly relevant and provides scientific evidence of a direct role for oxidative/nitrosative stress cellular damage in the general symptomatology of FEP and possibly in other disorders with psychotic symptoms. In a comparable cohort of patients, it has been reported that cognitive deficits are related to oxidative stress ([@CIT0029]).

As previously described, the longitudinal design of this study allowed to analyze the evolution of the inflammatory response taking place in FEP patients. The comparison of the data obtained in the 2 selected time-points illustrates the complex and continuous dynamic changes of the inflammatory response in the natural course of incipient psychosis. This complexity might be one of the causes of controversy regarding the specific role of inflammatory mediators in the pathophysiology of the different types of psychotic disorders ([@CIT0032]) and the difficulties in the design and proper use of treatment strategies based on classical antiinflammatory drugs, producing in most cases only relatively modest improvements in clinical symptoms in the early stage of schizophrenia ([@CIT0039]).

The results of the multivariate analysis show potential risk/protective factors common in both baseline and follow-up visits. This is the case of COX2 protein levels in PBMCs as a risk factor and 15d-PGJ~2~ plasma levels as a putative protection factor. However, other plausible biomarkers have lost their validity (ie, IκBα). These results illustrate how one biomarker could be useful in a limited phase of the natural course of the disease (status biomarker), but others are more general for all the phases of the disease (trait biomarker), as has been shown for specific cytokines ([@CIT0033]).

The reformulation of the traditional conception of the psychotic illness, being now considered as a heterogeneous disorder with multisystemic impact in addition to its psychiatric expression ([@CIT0023]), is clearly supported by these data. Recent studies compared the same immune biomarkers (eg, cytokines such as IFNγ) in plasma and postmortem brain tissue from control and subjects with schizophrenia and found similar alterations in both compartments, validating the concept that schizophrenia can be studied through systemic biomarkers ([@CIT0014]). A recent review suggested a link between peripheral inflammatory/immune processes and MRI-detected anomalies in the brain ([@CIT0008]), and studies in postmortem brain tissue from subjects with schizophrenia showed increased levels of some of the pro-/antiinflammatory and oxidative/nitrosative stress markers studied here (NFκB, COX2, TBARS) ([@CIT0038]). Our data might serve to elucidate whether the alterations of these inflammatory risk/protection biomarkers could have etiological relevance and not only utility for diagnosis and monitoring the evolution of the disease ([@CIT0002]).

The present study identifies vulnerability conditions related to PBMC pro-/antiinflammatory pathways in FEP patients. One special feature of the study is that it includes a wide spectrum of biochemical markers in both PBMCs and plasma, allowing to establish in-depth relationships between multiple components of the signalling pathways. In addition, we have used the DUBM variable that enhances the accuracy of the values obtained in each biomarker. Thus, this variable is especially relevant in the particular case of the proinflammatory/oxidative stress biomarkers PGE~2~ and TBARS, which significantly increase depending on the days between diagnosis and the moment of blood extraction. Additional studies that analyze inflammatory/immune biomarkers in psychiatric disease should take into account and control for this variable.

Limitations {#s20}
-----------

The present results may also explain one possible limitation reported in our first study ([@CIT0011]) about the role of stress in the observed changes: stress exposure could be one of the factors implicated in the onset of FEP ([@CIT0017]), and stress could contribute to the observed shift towards enhanced pro- vs antiinflammatory signalling ([@CIT0009]). However, current results indicate a clear evolution after 1 year (not only were intracellular components of the inflammatory response increased, but also the majority of resultant proinflammatory soluble elements and the oxidative/nitrosative stress markers). Also, the deregulation of the balance is permanent in chronic schizophrenic inpatients with a 13-year history of psychosis ([@CIT0030]). This evolution suggests that the inflammatory process is not merely due to acute stress exposure in the beginning of FEP.

Control subjects were not followed 6 months after baseline as patients were, and this could be considered a major limitation. When this study was designed, our hypothesis was that the pro-/antiinflammatory mediators analyzed did not significantly change in 6 months in control subjects. However, this possibility exists, and the interpretation of the results obtained 6 months after baseline with regards to control subjects should be done with caution. The main objective of the experimental design made was to study the intra-subject evolution of the disease between both time points.

It is worth noting that 75% of the FEP patients included in our study were under atypical antipsychotic treatment, and there is increasing evidence on the potential antiinflammatory effects of antipsychotics ([@CIT0040]; [@CIT0033]; [@CIT0027]). Nevertheless, we tried to control the possible confounding effect of antipsychotic treatment through a multiple linear regression analysis.

In addition, each antipsychotic group and lithium have very different impacts on metabolic signalling (weight gain), and with the approximation made with the chlorpromazine equivalents, their differential profile could be lost. To resolve this issue, we analyzed if there are differences in weight gain between basal and follow-up time points studied and between the different antipsychotic groups and lithium, respectively (supplementary Tables S6-8) and there were no significant differences.

Finally, it would be necessary to determine if the peripheral changes found in inflammatory-related molecules in FEP subjects could also take place at a central level.

Conclusion {#s21}
==========

In conclusion, this follow-up study corroborates the existence of a deregulated systemic pro-/antiinflammatory balance in FEP, which becomes more severe during the initial 1 year after the diagnosis. The multivariate analysis applied shows potential risk/protective factors in both time points studied (COX-2 protein levels in PBMCs and 15d-PGJ~2~ plasma levels) that can be considered trait markers and other specific state biomarkers (initial: IκBα; 1-year evolution: NO^−^ ~2~ and TBARS). Striking results come from the multiple linear regression approach, which shows how one of the targets of antipsychotic treatment may be the restoration of the inflammatory balance. Finally, from a clinical point of view, the inverse relationship found between the final product of oxidative/nitrosative cellular damage TBARS and the GAF scale is especially relevant in order to justify the development of antioxidant/antiinflammatory treatment strategies not only for established schizophrenia but also for earlier stages of a psychotic disorder.
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[^1]: \*FLAMM-PEPs is a multicentric, collaborative, and translational group inside CIBERSAM with the aim to study inflammatory pathways in psychosis both as possible biomarkers and as possible new therapeutical targets incorporated in the PEPs study, a research project in first episodes of psychosis.
